Arbor Pharma Targets ‘Alcohol Use Disorder’ Drug

Specialty pharma company Arbor Pharmaceuticals has acquired XenoPort, Inc. (NASDAQ: XNPT), maker of Horizant, a potential treatment for patients with “alcohol use disorder.” XenoPort develops and commercializes a portfolio of product candidates for the treatment of neurological and other disorders in the United States. The company has entered into a clinical trial agreement with the National Institute on Alcohol Abuse and Alcoholism. Arbor will pay $7.03 per share in cash, or a total equity value of approximately $467 million. Centerview Partners is serving as exclusive financial advisor to XenoPort, and Weil, Gotshal & Manges LLP is serving as legal advisor to XenoPort.... Read More »